MARKET COMPOSITE
Market TodayThemes and Stocks SummaryThematic Stock SearchDaily Refresh Schedule
KLDO - Kaleido Biosciences Inc
$9.58
-0.23(-2.34%)9:00:00 PM 3/2/2021
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company offers product candidates for the treatment of urea cycle disorders; hepatic encephalopathy; infections caused by multi-drug resistant bacteria; cardiometabolic and liver diseases; and immune oncology. It has a collaboration agreement with Gustave Roussy Cancer Center to develop microbiome metabolic therapies in immuno-oncology; a research collaboration with Washington University School of Medicine to explore the influence of microbiome metabolic therapies on microbial and host physiology and metabolism; and a research collaboration with Janssen to prevent childhood-onset of atopic, immune, and metabolic conditions. The company was founded in 2015 and is headquartered in Lexington, Massachusetts.
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

No summary
Related Topics
Peers

Related Peers

Stock news

    03/1/2021KLDO
    Kaleido Biosciences to Present at Chardan’s 3rd Annual Microbiome Medicines Summit

    LEXINGTON, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced that Dan Menichella, President and Chief Executive Officer of Kaleido will present a corporate overview and host 1x1 meetings with investors during Chardan’s 3rd Annual Microbiome Medicines Summit. The presentation will take place vi...

    02/11/2021KLDO
    Kaleido Biosciences Announces the Exercise of the Underwriters’ Option to Purchase Additional Shares of Common Stock

    LEXINGTON, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced that, in connection with its previously announced underwritten public offering of common stock, the underwriters have fully exercised their option to purchase an additional 787,500 shares of common stock from the Company. The exercise...

    02/9/2021KLDO
    Benzinga's Top Ratings Upgrades, Downgrades For February 9, 2021

    Upgrades For HSBC Holdings PLC (NYSE:HSBC), RBC Capital upgraded the previous rating of Underperform to Sector Perform. For the third quarter, HSBC Holdings had an EPS of $0.07, compared to year-ago quarter EPS of $0.15. At the moment, the stock has a 52-week-high of $38.61 and a 52-week-low of $17.95. HSBC Holdings closed at $26.82 at the end of the last trading period. According to Northcoast Research, the prior rating for Chipotle Mexican Grill Inc (NYSE:CMG) was changed from Neutral to Buy. ...

    02/9/2021KLDO
    What Is The Ownership Structure Like For Kaleido Biosciences, Inc. (NASDAQ:KLDO)?

    If you want to know who really controls Kaleido Biosciences, Inc. ( NASDAQ:KLDO ), then you'll have to look at the...

    02/4/2021KLDO
    Kaleido Biosciences Announces Pricing of Public Offering of Common Stock

    LEXINGTON, Mass., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced the pricing of an underwritten public offering of 5,250,000 shares of its common stock at a public offering price of $11.50 per share. In addition, Kaleido has granted the underwriters a 30-day option to purchase up to an additional 7...

    02/3/2021KLDO
    Kaleido Biosciences Announces Proposed Public Offering of Common Stock

    LEXINGTON, Mass., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced that it intends to sell, subject to market and other conditions, $50 million of shares of its common stock in an underwritten public offering. Kaleido also intends to grant the underwriters a 30-day option to purchase an additional $7...

    01/20/2021KLDO
    Kaleido Biosciences to Present at the Keystone Symposium “Harnessing the Microbiome for Disease Prevention and Therapy” Conference

    LEXINGTON, Mass., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), today announced Johan van Hylckama Vlieg, Ph.D., Chief Scientific Officer, will present at the Keystone Symposium “Harnessing the Microbiome for Disease Prevention and Therapy” conference this afternoon at 12:15 p.m. MST. The presentation will provide an update on progress with the Kaleido MMTTM platform, including a review of the K031 COVID-19 study interim data that were announced on January 14, 2021....